365 related articles for article (PubMed ID: 27721184)
1. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study.
Mansur RB; Ahmed J; Cha DS; Woldeyohannes HO; Subramaniapillai M; Lovshin J; Lee JG; Lee JH; Brietzke E; Reininghaus EZ; Sim K; Vinberg M; Rasgon N; Hajek T; McIntyre RS
J Affect Disord; 2017 Jan; 207():114-120. PubMed ID: 27721184
[TBL] [Abstract][Full Text] [Related]
2. Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders.
Mansur RB; Zugman A; Ahmed J; Cha DS; Subramaniapillai M; Lee Y; Lovshin J; Lee JG; Lee JH; Drobinin V; Newport J; Brietzke E; Reininghaus EZ; Sim K; Vinberg M; Rasgon N; Hajek T; McIntyre RS
Eur Neuropsychopharmacol; 2017 Nov; 27(11):1153-1162. PubMed ID: 28867303
[TBL] [Abstract][Full Text] [Related]
3. Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?
Mansur RB; Lee Y; Subramaniapillai M; Brietzke E; McIntyre RS
Neuropharmacology; 2018 Jul; 136(Pt B):335-342. PubMed ID: 29481915
[TBL] [Abstract][Full Text] [Related]
4. The effect of atorvastatin on cognition and mood in bipolar disorder and unipolar depression patients: A secondary analysis of a randomized controlled trial.
Fotso Soh J; Almadani A; Beaulieu S; Rajji T; Mulsant BH; Su CL; Renaud S; Mucsi I; Torres-Platas SG; Levinson A; Schaffer A; Dols A; Cervantes P; Low N; Herrmann N; Mantere O; Rej S
J Affect Disord; 2020 Feb; 262():149-154. PubMed ID: 31733459
[TBL] [Abstract][Full Text] [Related]
5. Neural correlates of improved executive function following erythropoietin treatment in mood disorders.
Miskowiak KW; Vinberg M; Glerup L; Paulson OB; Knudsen GM; Ehrenreich H; Harmer CJ; Kessing LV; Siebner HR; Macoveanu J
Psychol Med; 2016 Jun; 46(8):1679-91. PubMed ID: 26996196
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of brexpiprazole for bipolar depression.
Brown ES; Khaleghi N; Van Enkevort E; Ivleva E; Nakamura A; Holmes T; Mason BL; Escalante C
J Affect Disord; 2019 Apr; 249():315-318. PubMed ID: 30802696
[TBL] [Abstract][Full Text] [Related]
7. Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial.
Petersen JZ; Schmidt LS; Vinberg M; Jørgensen MB; Hageman I; Ehrenreich H; Knudsen GM; Kessing LV; Miskowiak KW
Trials; 2018 Nov; 19(1):611. PubMed ID: 30400939
[TBL] [Abstract][Full Text] [Related]
8. Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study.
Yatham LN; Mackala S; Basivireddy J; Ahn S; Walji N; Hu C; Lam RW; Torres IJ
Lancet Psychiatry; 2017 Mar; 4(3):208-217. PubMed ID: 28185899
[TBL] [Abstract][Full Text] [Related]
9. Cognitive deficits in bipolar disorders: Implications for emotion.
Lima IMM; Peckham AD; Johnson SL
Clin Psychol Rev; 2018 Feb; 59():126-136. PubMed ID: 29195773
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder.
Cha DS; Best MW; Bowie CR; Gallaugher LA; Woldeyohannes HO; Soczynska JK; Lewis G; MacQueen G; Sahakian BJ; Kennedy SH; Lui JP; Mansur RB; McIntyre RS
J Affect Disord; 2017 Mar; 210():57-65. PubMed ID: 28013123
[TBL] [Abstract][Full Text] [Related]
11. Targeting Treatments to Improve Cognitive Function in Mood Disorder: Suggestions From Trials Using Erythropoietin.
Miskowiak KW; Rush AJ; Gerds TA; Vinberg M; Kessing LV
J Clin Psychiatry; 2016 Dec; 77(12):e1639-e1646. PubMed ID: 27835716
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects of obesity on cognitive functions in individuals at ultra high risk for bipolar disorder: Results from the global mood and brain science initiative.
McIntyre RS; Mansur RB; Lee Y; Japiassú L; Chen K; Lu R; Lu W; Chen X; Li T; Xu G; Lin K
Bipolar Disord; 2017 Mar; 19(2):128-134. PubMed ID: 28493605
[TBL] [Abstract][Full Text] [Related]
13. Similar profiles of cognitive domain deficits between medication-naïve patients with bipolar II depression and those with major depressive disorder.
Liu T; Zhong S; Wang B; Liao X; Lai S; Jia Y
J Affect Disord; 2019 Jan; 243():55-61. PubMed ID: 30227315
[TBL] [Abstract][Full Text] [Related]
14. A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression.
Soczynska JK; Kennedy SH; Alsuwaidan M; Mansur RB; Li M; McAndrews MP; Brietzke E; Woldeyohannes HO; Taylor VH; McIntyre RS
Bipolar Disord; 2017 May; 19(3):198-213. PubMed ID: 28599348
[TBL] [Abstract][Full Text] [Related]
15. A meta-analytic investigation of cognitive remediation for mood disorders: Efficacy and the role of study quality, sample and treatment factors.
Goldberg Z; Kuslak B; Kurtz MM
J Affect Disord; 2023 Jun; 330():74-82. PubMed ID: 36868388
[TBL] [Abstract][Full Text] [Related]
16. Mood and neuropsychological changes in women with midlife depression treated with escitalopram.
Wroolie TE; Williams KE; Keller J; Zappert LN; Shelton SD; Kenna HA; Reynolds MF; Rasgon NL
J Clin Psychopharmacol; 2006 Aug; 26(4):361-6. PubMed ID: 16855452
[TBL] [Abstract][Full Text] [Related]
17. Executive function impairments in depression and bipolar disorder: association with functional impairment and quality of life.
Cotrena C; Branco LD; Shansis FM; Fonseca RP
J Affect Disord; 2016 Jan; 190():744-753. PubMed ID: 26606718
[TBL] [Abstract][Full Text] [Related]
18. Cognitive effects of creatine monohydrate adjunctive therapy in patients with bipolar depression: Results from a randomized, double-blind, placebo-controlled trial.
Toniolo RA; Fernandes FBF; Silva M; Dias RDS; Lafer B
J Affect Disord; 2017 Dec; 224():69-75. PubMed ID: 27890303
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC
J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334
[TBL] [Abstract][Full Text] [Related]
20. The prevalence and illness characteristics of DSM-5-defined "mixed feature specifier" in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project.
McIntyre RS; Soczynska JK; Cha DS; Woldeyohannes HO; Dale RS; Alsuwaidan MT; Gallaugher LA; Mansur RB; Muzina DJ; Carvalho A; Kennedy SH
J Affect Disord; 2015 Feb; 172():259-64. PubMed ID: 25451425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
